Prof. Sibylle Loibl, MD, PhD, is the Chief Executive Officer and Chair of the German Breast Group (GBG), one of the leading study groups worldwide. She devotes the majority of her time to clinical trial research at GBG and at her clinical affiliations University of Frankfurt, Sana Klinikum in Offenbach and Oncology Bethanien in Frankfurt.
Prof. Loibl is an associate professor at the University of Frankfurt. She graduated from the University of Heidelberg and completed her fellowship and residency as a gynecologist and obstetrician at the University of Heidelberg and Frankfurt.
Prof. Loibl is internationally renowned in the fields of neoadjuvant breast cancer, breast cancer during pregnancy, and breast cancer in young women. She developed the translational research division within the GBG and has led numerous translational projects as well as research projects founded by the EU Commission. She has led and participated in more than 100 national and international clinical trials in the field of breast cancer.
In 2014 she joined the Executive Board of the Breast International Group (BIG). As a medical expert, she serves on several international steering committees, translational research committees, and independent data monitoring committees.
Prof. Loibl has co-authored more than 220 MEDLINE-listed scientific papers, in addition to more than 200 original and peer-reviewed articles, as well as 29 books or book chapters, and she has actively contributed to more than 200 national and international congresses. She is an active member of numerous national and international organizations such as the American Society of Clinical Oncology (ASCO), European Society of Medical Oncology (ESMO), European Organization for Research and Treatment of Cancer/Translational Research Network for Gynaecological Cancers (EORTC-TRAFO), and the European Society of Gynaecologic Oncology (ESGO).